The short answer
Reported data show a single 5 mg tirzepatide dose reducing peak concentrations of ethinyl estradiol, norgestimate and norelgestromin by 59%, 66% and 55% respectively, with overall exposure down around 20%. Semaglutide, liraglutide and dulaglutide did not show this effect.
Key facts
- Compound affected
- Tirzepatide
- Ethinyl estradiol peak
- Reduced ~59%
- Norgestimate peak
- Reduced ~66%
- Norelgestromin peak
- Reduced ~55%
- Overall exposure
- Down ~20%
- Not affected
- Semaglutide, liraglutide, dulaglutide
- Review
- Skelley 2024 (PMID 37940101)
Why one compound behaves differently
Tirzepatide engages the GIP receptor as well as GLP-1, and the reported effect on gastric emptying is greater than that of the pure GLP-1 agonists. A larger delay in gastric emptying produces a larger effect on the absorption of anything taken by mouth alongside it, so the interaction tracks the magnitude of the underlying pharmacology.
Why dose escalation compounds it
Delayed gastric emptying attenuates with continued exposure at a stable dose. The effect is largest when a dose is new. A regimen that steps up through several doses therefore reintroduces a strong delay each time it escalates, rather than producing one adaptation that then settles. That is why the reported label position attaches to escalations and not only to starting.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The gap between peak and total, and why it matters here
Peak concentrations fell by 55 to 66% while overall exposure fell by around 20%. That gap is the signature of an absorption-rate effect rather than a loss of drug. For a hormonal contraceptive, though, this is the case where the peak is not merely cosmetic, which is why the finding attracted labelling attention rather than being noted and set aside.
What the label position is
The FDA labelling directs that patients using oral hormonal contraceptives switch to a non-oral method or add a barrier method for four weeks after initiation and for four weeks after each dose escalation. That is a statement of what a regulator has required on a label, reported here as a fact about the label. It is not advice, and decisions of this kind belong with a prescriber.
Why treating this as a class property is the common error
Coverage of GLP-1 drug interactions generally speaks about the class as a unit. Skelley and colleagues examined tirzepatide alongside the GLP-1 receptor agonists in the Journal of the American Pharmacists Association in 2024, and the finding is a contrast rather than a shared property. Applying tirzepatide's interaction profile to semaglutide overstates it; applying semaglutide's to tirzepatide understates it.
The boundary
Tirzepatide and the other compounds named are licensed medicines. Nothing supplied on this site is any of them, is related to them, or interacts with any medicine a person may be taking, because nothing here is for human use in any form.
Quick reference
| Compound | Effect on oral contraceptive absorption |
|---|---|
| Tirzepatide | Peak reduced 55-66%; exposure down ~20% |
| Semaglutide | Not shown to affect bioavailability |
| Liraglutide | Not shown to affect bioavailability |
| Dulaglutide | Not shown to affect bioavailability |
Frequently asked questions
Do all GLP-1 drugs affect oral contraceptives?
No. The reported effect is tirzepatide-specific; semaglutide, liraglutide and dulaglutide did not show it.
Why does tirzepatide differ?
It engages the GIP receptor as well as GLP-1 and produces a greater reported delay in gastric emptying, which affects absorption of anything taken by mouth alongside it.
Why does the label mention dose escalation?
The gastric emptying delay is largest when a dose is new and attenuates with continued exposure, so each escalation reintroduces it.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedSkelley JW et al., The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception. J Am Pharm Assoc 2024 (PMID 37940101)pubmed.ncbi.nlm.nih.gov
- PubMedShaefer CF Jr et al. Postgrad Med 2015 (PMID 26371721)pubmed.ncbi.nlm.nih.gov
- FDAFDA Drug Approval Searchaccessdata.fda.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- Where the Thyroid Warning Came FromRodents given GLP-1 agonists developed C-cell hyperplasia and tumours. The 2010 paper that established it, and why it was an on-target effect.
- Normal Human Thyroid Has No Detectable GLP-1 ReceptorsWaser 2011 measured incretin receptors in rodent and human thyroid. The species difference is stark - and the human receptor picture points at GIP, not GLP-1.
- The Strongest Warning a Label CarriesA boxed warning is the most serious labelling a regulator applies. It does not mean a risk is proven - it means the consequence would be severe.
- The Hormone That Empties the Gallbladder, SuppressedCholecystokinin makes the gallbladder contract. GLP-1 suppresses cholecystokinin secretion - which is the identified mechanism behind the biliary events.
- What the Meta-Analysis EstablishedHe 2022 pooled randomised trials on gallbladder and biliary disease with GLP-1 receptor agonists. Why pooling was necessary for an outcome this infrequent.